Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial
Clinical Infectious Diseases · 2024
DOI: 10.1093/cid/ciae306 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Infectious Diseases, 2024. Verfasst von Karen C Tran und 45 weiteren Autor:innen. Beteiligte Einrichtung: Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada. Hauptthemen laut MEDLINE: Losartan, Hospitalization, COVID-19, COVID-19 Drug Treatment. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Canadian Institutes of Health Research.
Abstract (Originalsprache)
Background
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) down-regulates angiotensin-converting enzyme 2, potentially increasing angiotensin II. We hypothesized that losartan compared to usual care decreases mortality and is safe in patients hospitalized with coronavirus disease 2019 (COVID-19). We aimed to evaluate the effect of losartan versus usual care on 28-day mortality in patients hospitalized for acute COVID-19.
Methods
Eligibility criteria included adults admitted for acute COVID-19. Exclusion criteria were hypotension, hyperkalemia, acute kidney injury, and use of angiotensin receptor blockers (ARBs) or angiotensin-converting enzyme inhibitors within 7 days. Participants were randomized to losartan 25–100 mg/day orally for the hospital duration or 3 months or the control arm (usual care) in 29 hospitals in Canada and France. The primary outcome was 28-day mortality. Secondary outcomes were hospital mortality, organ support, and serious adverse events (SAEs).
Results
The trial was stopped early because of a serious safety concern with losartan. In 341 patients, any SAE and hypotension were significantly higher in the losartan versus usual care groups (any SAE: 39.8% vs 27.2%, respectively, P = .01; hypotension: 30.4% vs 15.3%, respectively, P < .001) in both ward and intensive care patients. The 28-day mortality did not differ between losartan (6.5%) versus usual care (5.9%) (odds ratio, 1.11 [95% confidence interval, .47–2.64]; P = .81), nor did organ dysfunction or secondary outcomes.
Conclusions
Caution is needed in deciding which patients to start or continue using ARBs in patients hospitalized with pneumonia to mitigate risk of hypotension, acute kidney injury, and other side effects. ARBs should not be added to care of patients hospitalized for acute COVID-19. Clinical Trials Registration NCT04606563.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of General Internal Medicine, Vancouver General Hospital, University of British Columbia, Vancouver, Canada.
- Service de Médecine Intensive-Réanimation, Centre Hospitalier Universitaire d'Angers, Angers, France.
- McGill's Interdisciplinary Initiative in Infection and Immunity, Divisions of Infectious Diseases and Medical Microbiology, McGill University Health Centre, Montreal, Quebec, Canada.
- Service de Médecine Intensive-Réanimation, Nouvel Hôpital Civil, Hôpitaux Universitaires de Strasbourg, Strasbourg, France.
- Centre for Health Evaluation and Outcome Science, St Paul's Hospital and University of British Columbia, Vancouver, Canada.
- Division of Critical Care Medicine, and Centre for Heart Lung Innovation, St Paul's Hospital, Vancouver, Canada.
Förderung
- CIHR
- Canadian Institutes of Health Research
Zitieren
APA
Tran, K. C., Asfar, P., Cheng, M., Demiselle, J., Singer, J., Lee, T., Sweet, D., Boyd, J., Walley, K., Haljan, G., Sharif, O., Geri, G., Auchabie, J., Quenot, J. P., Lee, T. C., Tsang, J., Meziani, F., Lamontagne, F., Dubee, V., …, & ARBs CORONA II Team (2024). Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciae306
Vancouver
Tran KC, Asfar P, Cheng M, Demiselle J, Singer J, Lee T, et al. Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial. Clinical Infectious Diseases. 2024. doi:10.1093/cid/ciae306
BibTeX
@article{Tran2024,
author = {Tran, Karen C and Asfar, Pierre and Cheng, Matthew and Demiselle, Julien and Singer, Joel and Lee, Terry and Sweet, David and Boyd, John and Walley, Keith and Haljan, Greg and Sharif, Omar and Geri, Guillaume and Auchabie, Johann and Quenot, Jean-Pierre and Lee, Todd C and Tsang, Jennifer and Meziani, Ferhat and Lamontagne, Francois and Dubee, Vincent and Lasocki, Sigismond and Ovakim, Daniel and Wood, Gordon and Turgeon, Alexis and Cohen, Yves and Lebas, Eddy and Goudelin, Marine and Forrest, David and Teale, Alastair and Mira, Jean-Paul and Fowler, Robert and Daneman, Nick and Adhikari, Neill K J and Gousseff, Marie and Leroy, Pierre and Plantefeve, Gaetan and Rispal, Patrick and Courtois, Roxane and Winston, Brent and Reynolds, Steve and Birks, Peter and Bienvenu, Boris and Tadie, Jean-Marc and Talarmin, Jean-Philippe and Ansart, Severine and Russell, James A and ARBs CORONA II Team, ARBs CORONA II Team},
title = {Effects of Losartan on Patients Hospitalized for Acute COVID-19: A Randomized Controlled Trial},
journal = {Clinical Infectious Diseases},
year = {2024},
doi = {10.1093/cid/ciae306}
}
EUVIMED